Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tracleer in NYHA Class II Pulmonary Arterial Hypertension (EARLY)
NCT00091715Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2004
- Primary completion
- Nov 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Bosentan Arm with Placebo Arm (2 arms). Primary endpoints: 6-minute walk distance at 24 weeks and Pulmonary Vascular Resistance at 24 weeks. Started Apr 2004; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00091715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091715.